

# Karen Kelly

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3465947/karen-kelly-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

148  
papers

9,760  
citations

44  
h-index

97  
g-index

157  
ext. papers

11,299  
ext. citations

5.3  
avg, IF

5.6  
L-index

#	Paper	IF	Citations
148	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.. <i>JTO Clinical and Research Reports</i> , <b>2022</b> , 3, 100262	1.4	1
147	Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2021</b> , 19, 1441-1464	7.3	16
146	Patient Knowledge and Expectations About Return of Genomic Results in a Biomarker-Driven Master Protocol Trial (SWOG S1400GEN). <i>JCO Oncology Practice</i> , <b>2021</b> , 17, e1821-e1829	2.3	1
145	Guidelines for the Evaluation of Pulmonary Nodules Detected Incidentally or by Screening: A Survey of Radiologist Awareness, Agreement, and Adherence From the Watch the Spot Trial. <i>Journal of the American College of Radiology</i> , <b>2021</b> , 18, 545-553	3.5	3
144	Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 335-341	3.5	0
143	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). <i>Immunotherapy</i> , <b>2021</b> , 13, 727-734	3.8	2
142	SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 178-186	4.9	1
141	A Phase II Study of Telisotuzumab Vedotin in Patients With c-MET-positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP Sub-study S1400K, NCT03574753). <i>Clinical Lung Cancer</i> , <b>2021</b> , 22, 170-177	4.9	11
140	Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , <b>2021</b> , 1,	3.6	4
139	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors <b>2021</b> , 9,		4
138	Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760) <b>2021</b> , 9,		5
137	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5781-5792	12.9	5
136	Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1368-1377	13.4	6
135	Durable Responses to Afatinib as First-line Therapy for HER2-mutated Metastatic Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, e15-e20	4.9	4
134	Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 5329-5337	12.9	1
133	Efficacy and immune-related adverse event associations in avelumab-treated patients <b>2020</b> , 8,		5
132	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1589-1601	21.7	26

131	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study <b>2020</b> , 8,		6
130	CT Volumetry and Basic Texture Analysis as Surrogate Markers in Advanced Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 225-231	4.9	1
129	SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1847-1852	8.9	38
128	SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1839-1846	8.9	31
127	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. <i>JAMA Oncology</i> , <b>2019</b> , 5, 393-401	13.4	178
126	Role of Targeted Therapy and Immune Checkpoint Blockers in Advanced Non-Small Cell Lung Cancer: A Review. <i>Oncologist</i> , <b>2019</b> , 24, 1270-1284	5.7	14
125	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 555-559	3.6	3
124	Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2537-2547	2.2	21
123	SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy). <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 1853-1859	8.9	33
122	Survival benefits associated with surgery for advanced non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2019</b> , 157, 1620-1628	1.5	9
121	Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. <i>Nature Medicine</i> , <b>2019</b> , 25, 141-151	50.5	284
120	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2019</b> , 14, 298-303	8.9	10
119	Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. <i>Cancer</i> , <b>2018</b> , 124, 2010-2017	6.4	65
118	Update on International Cooperative Groups Studies in Thoracic Malignancies: The Emergence of Immunotherapy. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 377-386	4.9	
117	Smoking, Sex, and Non-Small Cell Lung Cancer: Steroid Hormone Receptors in Tumor Tissue (S0424). <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 734-742	9.7	25
116	Stereotactic Ablative Radiation Therapy Induces Systemic Differences in Peripheral Blood Immunophenotype Dependent on Irradiated Site. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2018</b> , 101, 1259-1270	4	34
115	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1171-1182	8.9	9
114	Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 84-92	4.9	3

113	Treatment of Extensive-Stage Small Cell Lung Cancer <b>2018</b> , 525-535.e5		
112	Phase 1B Study of Mometotinib Combined With Trametinib in Metastatic, Kirsten Rat Sarcoma Viral Oncogene Homolog-Mutated Non-Small-Cell Lung Cancer After Platinum-Based Chemotherapy Treatment Failure. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e853-e859	4.9	14
111	Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase Ib Study. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5543-5551	12.9	11
110	A phase I trial of topotecan plus tivantinib in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2018</b> , 82, 723-732	3.5	5
109	Association of efficacy and adverse events of special interest of avelumab in the JAVELIN solid tumor and JAVELIN Merkel 200 trials.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3057-3057	2.2	1
108	Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 101-114	21.7	45
107	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 3298-3306	2.2	57
106	Response to H. Nabi et al. <i>Journal of the National Cancer Institute</i> , <b>2018</b> , 110, 1424-1425	9.7	
105	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, 531-543	4.9	2
104	Increasing Rates of No Treatment in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Propensity-Matched Analysis. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 437-445	8.9	28
103	Preclinical Evaluation of MET Inhibitor INC-280 With or Without the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 281-285	4.9	30
102	Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 803-811	21.7	198
101	Treatment of Locally Advanced Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2017</b> , 31, 45-57	3.1	6
100	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 599-610	21.7	215
99	A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 556-566	8.9	30
98	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2017</b> , 18, 1-4	4.9	6
97	A Model to Predict the Use of Surgical Resection for Advanced-Stage Non-Small Cell Lung Cancer Patients. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 1665-1672	2.7	9
96	Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2117-2124	2.2	415

95	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2885-2892	2.2	48
94	Effects of imputation on correlation: implications for analysis of mass spectrometry data from multiple biological matrices. <i>Briefings in Bioinformatics</i> , <b>2017</b> , 18, 312-320	13.4	20
93	The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1636-1645	8.9	41
92	Clinical predictors of survival in young patients with small cell lung cancer: Results from the California Cancer Registry. <i>Lung Cancer</i> , <b>2017</b> , 112, 165-168	5.9	10
91	Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). <i>Journal of Thoracic Oncology</i> , <b>2017</b> , 12, 1299-1308	8.9	20
90	Multivariate two-part statistics for analysis of correlated mass spectrometry data from multiple biological specimens. <i>Bioinformatics</i> , <b>2017</b> , 33, 17-25	7.2	2
89	Infusion-related reactions with administration of avelumab: mild and manageable side effects. <i>Translational Cancer Research</i> , <b>2017</b> , 6, S1296-S1298	0.3	2
88	Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. <i>Clinical Lung Cancer</i> , <b>2016</b> , 17, 113-8.e1-2	4.9	9
87	Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: Safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3055-3055	2.2	10
86	Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 5533-5533	2.2	88
85	Serum phosphatidylethanolamine levels distinguish benign from malignant solitary pulmonary nodules and represent a potential diagnostic biomarker for lung cancer. <i>Cancer Biomarkers</i> , <b>2016</b> , 16, 609-17	3.8	31
84	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 946-63	8.9	145
83	Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1075114	7.2	31
82	Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4321-6	12.9	47
81	Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 2480-6	12.9	53
80	Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 110-5	8.9	20
79	Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2015</b> , 24, 1716-23	4	44
78	Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-III A Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4007-14	2.2	238

77	Differential N-Glycosylation Patterns in Lung Adenocarcinoma Tissue. <i>Journal of Proteome Research</i> , <b>2015</b> , 14, 4538-49	5.6	42
76	Clinical Trials Integrating Immunotherapy and Radiation for Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2015</b> , 10, 1685-93	8.9	38
75	Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. <i>Cancer</i> , <b>2015</b> , 121, 4165-72	6.4	14
74	Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. <i>Cancer Prevention Research</i> , <b>2015</b> , 8, 410-8	3.2	59
73	A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. <i>Clinical Lung Cancer</i> , <b>2015</b> , 16, 340-7	4.9	31
72	Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 301	5.3	3
71	Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2463-70	2.2	55
70	Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: approach to subtyping progressive disease and clinical implications. <i>Clinical Lung Cancer</i> , <b>2014</b> , 15, 1-6	4.9	67
69	Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis. <i>Lung Cancer</i> , <b>2014</b> , 85, 264-9	5.9	44
68	50 Years of progress in the systemic therapy of non-small cell lung cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2014</b> , 177-89	7.1	75
67	Twenty years post-NIH Revitalization Act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials. <i>Cancer</i> , <b>2014</b> , 120 Suppl 7, 1091-6	6.4	210
66	Chip-based nLC-TOF-MS is a highly stable technology for large-scale high-throughput analyses. <i>Analytical and Bioanalytical Chemistry</i> , <b>2013</b> , 405, 4953-8	4.4	33
65	Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. <i>Clinical Lung Cancer</i> , <b>2013</b> , 14, 627-35	4.9	9
64	A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2013</b> , 3, 219	5.3	9
63	Integration of targeted therapy in the management of locally advanced, unresectable non-small-cell lung cancer. <i>Lung Cancer Management</i> , <b>2013</b> , 2, 75-85	2.6	
62	Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. <i>Journal of Thoracic Oncology</i> , <b>2013</b> , 8, 1519-28	8.9	18
61	Treatment paradigms in advanced non-small-cell lung cancer. <i>Clinical Advances in Hematology and Oncology</i> , <b>2013</b> , 11, 629-39	0.6	4
60	N-Glycan profiling of dried blood spots. <i>Analytical Chemistry</i> , <b>2012</b> , 84, 396-402	7.8	54



59	Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and inpatient tumor heterogeneity. <i>Clinical Lung Cancer</i> , <b>2012</b> , 13, 321-5	4.9	20
58	Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 1041-8	8.9	23
57	SWOG S0533: A pilot trial of cisplatin (C)/etoposide (E)/radiotherapy (RT) followed by consolidation docetaxel (D) and bevacizumab (B) (NSC-704865) in three cohorts of patients (pts) with inoperable locally advanced stage III non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 7018-7018	2.2	5
56	Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 372-7	8.9	13
55	Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. <i>Journal of Thoracic Oncology</i> , <b>2011</b> , 6, 115-20	8.9	40
54	Oral iloprost improves endobronchial dysplasia in former smokers. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 793-802	3.2	89
53	Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4747-54	2.2	57
52	Summary of selected presentations from the 8th annual targeted therapy in lung cancer symposium. <i>Journal of Thoracic Oncology</i> , <b>2009</b> , 4, 930-5	8.9	
51	A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer. <i>Cancer Prevention Research</i> , <b>2009</b> , 2, 440-9	3.2	25
50	Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , <b>2008</b> , 61, 82-90	5.9	150
49	Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 2450-6	2.2	467
48	Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 463-7	2.2	156
47	Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3351-7	2.2	249
46	Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 3567-72	2.2	96
45	Biological agents in non-small cell lung cancer: a review of recent advances and clinical results with a focus on epidermal growth factor receptor and vascular endothelial growth factor. <i>Journal of Thoracic Oncology</i> , <b>2008</b> , 3, 664-73	8.9	31
44	Single-institution experience with pemetrexed and bevacizumab as salvage therapy in advanced non-small-cell lung cancer. <i>Clinical Lung Cancer</i> , <b>2007</b> , 8, 335-8	4.9	10
43	Current treatment paradigms for locally advanced non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2 Suppl 2, S77-85	8.9	33
42	Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 933-8	8.9	4

41	Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718. <i>Journal of Thoracic Oncology</i> , <b>2007</b> , 2, 440-4	8.9	4
40	EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. <i>Lancet Oncology</i> , <b>2007</b> , 8, 559-60	21.7	9
39	Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). <i>Clinical Lung Cancer</i> , <b>2006</b> , 8, 116-21	4.9	66
38	A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. <i>Cancer</i> , <b>2006</b> , 107, 781-92	6.4	91
37	Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 5025-33	2.2	133
36	Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 3652-6	12.9	54
35	Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 4405-11	2.2	121
34	Efficacy and safety of gefitinib in chemo-naïve patients with advanced non-small cell lung cancer treated in an Expanded Access Program. <i>Lung Cancer</i> , <b>2006</b> , 53, 331-7	5.9	10
33	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 991-995	8.9	
32	A phase I/II trial of stereotactic body radiation therapy (SBRT) for lung metastases: Initial report of dose escalation and early toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, S120-S127	4	21
31	A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer. <i>Investigational New Drugs</i> , <b>2006</b> , 24, 213-21	4.3	7
30	Phase II Trial of Paclitaxel, Carboplatin, and Topotecan with G-CSF Support in Previously Untreated Patients with Extensive Stage Small Cell Lung Cancer: Southwest Oncology Group 9914. <i>Journal of Thoracic Oncology</i> , <b>2006</b> , 1, 991-995	8.9	4
29	Therapeutic strategies for combined-modality therapy of locally advanced non-small-cell lung cancer: rationale for consolidation docetaxel therapy. <i>Clinical Lung Cancer</i> , <b>2005</b> , 7 Suppl 3, S93-7	4.9	3
28	Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3752-9	2.2	146
27	HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. <i>Oncologist</i> , <b>2005</b> , 10, 345-56	5.7	232
26	The role of targeted agents in adjuvant therapy for non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 5027s-5029s	12.9	10
25	Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 3125-37	2.2	152
24	ACCO: ASCO core curriculum outline. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2049-77	2.2	29



23	Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 8786-93	2.2	172
22	Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5022-6	12.9	44
21	A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 7229-37	12.9	21
20	Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 5439-46	12.9	48
19	Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. <i>Seminars in Oncology</i> , <b>2004</b> , 31, 3-7	5.5	20
18	Novel approaches for the treatment of small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , <b>2004</b> , 18, 499-518	3.1	5
17	Treatment of thymoma: a comparative study between Thailand and the United States and a review of the literature. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2004</b> , 27, 236-46	2.7	7
16	An elderly man with resectable lung cancer. <i>Oncology</i> , <b>2004</b> , 18, 234-40	1.8	
15	Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 290, 2149-58	27.4	2093
14	The benefits of achieving stable disease in advanced lung cancer. <i>Oncology</i> , <b>2003</b> , 17, 957-63; discussion 963, 968-70	1.8	5
13	Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. <i>Seminars in Oncology</i> , <b>2002</b> , 29, 87-94	5.5	44
12	Current role of irinotecan in the treatment of non-small-cell lung cancer. <i>Oncology</i> , <b>2002</b> , 16, 1153-62, 1165; discussion 1165-6 passim	1.8	3
11	Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3210-8	2.2	963
10	New chemotherapy agents for small cell lung cancer. <i>Chest</i> , <b>2000</b> , 117, 156S-162S	5.3	54
9	The inherited nature of lung cancer: a pilot study. <i>Lung Cancer</i> , <b>2000</b> , 30, 135-44	5.9	27
8	A phase I study of daily carboplatin and simultaneous accelerated, hyperfractionated chest irradiation in patients with regionally inoperable non-small cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>1998</b> , 40, 559-67	4	12
7	Is it time to reevaluate our approach to the treatment of brain metastases in patients with non-small cell lung cancer?. <i>Lung Cancer</i> , <b>1998</b> , 20, 85-91	5.9	65
6	Peptide amidating activity in human bronchoalveolar lavage fluid. <i>Lung Cancer</i> , <b>1996</b> , 14, 239-51	5.9	7

5	Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. <i>Analytical Biochemistry</i> , <b>1996</b> , 239, 153-9	3.1	23
4	Re: Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer. <i>Journal of the National Cancer Institute</i> , <b>1995</b> , 87, 767-767	9.7	3
3	Antigens in lung cancer: clinical radio-immunolocalization in lung cancer. <i>Lung Cancer</i> , <b>1993</b> , 9, 171-177	5.9	2
2	Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage. <i>Journal of Cellular Biochemistry</i> , <b>1993</b> , 17F, 175-83	4.7	10
1	Growth factors in lung cancer: possible etiologic role and clinical target. <i>Medical and Pediatric Oncology</i> , <b>1991</b> , 19, 450-8		4